Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

Viaderma.

19 Posts
| Omlaag ↓
  1. [verwijderd] 31 maart 2016 20:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    VDRM

    ViaDerma, Inc.

    A Division of ViaDerma, Inc. , A Public Company.

    Breakthrough Rapid Delivery of Nutrients and Medicines

    ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

    About Our Products



    Proprietary and Trade Secret Mechanism of Action

    ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

    The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

    This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

    The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

    Skin Layer Organization

    A second important result of RAIDS is that the topical antibiotic [b]kills all harmful Gram positive and Gram negative bacteria that have been available for testing.[/b] We believe this is the world’s strongest broad-spectrum topical antibiotic available.

    The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

    Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

    In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.

    APPLICATIONS & USAGE

    We are developing products in the following fields of use;

    Topical antibiotics

    Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

    Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.

    Topical toenail antifungal
    Acne
    Psoriasis
    Eczema
    Topical toenail antifungal

    Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

    Anti-viral formula

    Treats symptoms of Influenza which is a$4B/ year global market: Common

    Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
    Wound care

    Diabetic foot wounds.

    Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year
    Contact Details

    ViaDerma's global headquarters is located at
    8950 W. Olympic Blvd, Suite 576, Beverly Hills, CA 90211.

    We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.

    Phone: 310.871.3996

    Headlines Get Headlines for:
    Tuesday, August 5, 2014

    ViaDerma, Inc. Announces Strategic Partnership With The Brewer GroupPR Newswire (Tue, Aug 5)
    Tuesday, June 10, 2014

    VIADERMA INC FinancialsEDGAR Online Financials (Tue, Jun 10)
    Older Headlines - Most Recent Headlines

    --------------------------------------------------------------------------------

  2. [verwijderd] 31 maart 2016 20:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    TetraStem, Lead Product of ViaDerma, Inc., Hopes to Slow Rates of Diabetic Amputations

    GlobeNewswire via CMTX - Fri Nov 07, 7:54AM CST
    ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that has shown success in aiding the healing of diabetic wounds and therefore preventing amputations.

    Diabetes is a serious medical condition that affects how the body uses blood sugar. Because glucose is vital for your cells to have enough energy, too much of it can lead to major medical problems such as amputations. In 2010, roughly 8% of the American population had diabetes, or 25.8 million people. Of those 25.8 million diagnosed diabetics, 73,000 adults had non-traumatic lower-limb amputations, according to the American Diabetes Association.

    TetraStem has shown success in laboratory trials and found to be 99 percent effective against all bacteria. ViaDerma believes the application of TetraStem can maximize the healing of diabetic wounds before they require amputation.

    "TetraStem kills infection because of the proprietary, transdermal delivery that allows TetraStem to kill bacteria chemically and physically," says CEO of ViaDerma, Dr. Christopher Otiko. "We hope that the application of TetraStem can help reduce the number of amputations from diabetic wounds, thereby saving lives and increasing people's quality of life."


    Authorized Shares: 150,000,000 a/o Sep 30, 2015

    Outstanding Shares: 109,042,787 a/o Sep 30, 2015

    Float: 18,188,076 a/o Sep 30, 2015

    Par Value 0.001

    ------

    $VDRM COULD BE THE pharmacy stock of the year. This stock could run 30,000% here's why.

    1) EXTREMELY OVERSOLD and unknown
    2) ONLY 150 MILLION A\S! Makes it the TINIEST FLOAT VS PRICE out of ALL pharmacy stockso in the whole country!
    3) Pharmaceutical stocks have the LARGEST PERCENTAGE GAINS OUT OF ALL STOCKS IN THE MARKET on the big boards or the OTHER.
    4) Unusual sudden MASSIVE increase in volume since 3/7/16 LOOK.
    5) INSIDERS OWN 75 MILLION SHARES, that's right 75 MILLION!
    6) WON AWARD FOR THEIR DRUG
    7) STRONG HANDS HOLDING 11 million shares out of the TINY 18 million float.
    8) After being silent for ages 4 JUICY FILINGS came out in September so something could be up.
    9) THEY HAVE A PATENT which big boys have to be eyeing.

    VDRM IS A HIDDEN GOLDMINE

    THIS IS NOT A REGULAR PENNY STOCK. The LOWEST FLOAT vs price vs ALL PHARMA STOCKS IN THE COUNTRY. BIG BOARD OR OTC LAND. ALL OF THEM. Pharma stocks have the HIGHIGHEST EST percentage gain in big boards or penny stocks
  4. [verwijderd] 31 maart 2016 20:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    investorshub.advfn.com/ViaDerma-Inc-V...

    Mijn beste aandeel wat ik ooit heb gehad en misschien wel het beste aandeel op de hele OTC.

    Letterlijk een verborgen goudmijn. De float op dit aandeel is deze week bijna helemaal opgekocht.

    Er zijn dan ook niet veel aandelen meer beschikbaar en er gaat een ware run op komen. De producten die ze hebben hebben al Awards gewonnen, waaronder de Edison Award. Ook maken ze kwartaal op kwartaal meer winst en zijn ze schuldenvrij.

    Is is vrijwel niemand die verkoopt en alleenmaar kopers.

    Lees het allemaal door zou ik zeggen en geef uw mening. groetjes Daan.
  6. [verwijderd] 31 maart 2016 22:27

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik heb ze via Alex aangeschaft Marco. Volgens mij is het aanbod van de giro vrij beperkt. Of misschien moet je eerst wat papieren tekenen om USA aandelen te kopen.
  7. marco1975 1 april 2016 08:40

    • marco1975

      Lid sinds: 06 okt 2008

      Laatste bezoek: 24 mrt 2023

    • Aanbevelingen

      Ontvangen: 19

      Gegeven: 66

    •    Aantal posts: 830

    Nee hoor heb verder nooit problemen met amerikaanse aandelen. Maar kan hem niet vinden op naam of isin code. En voor dit geld is het nog wel een gokje waard.
  10. [verwijderd] 3 april 2016 08:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Viaderma Inc (OTCMKTS:VDRM) continues to surge on new developments of entering a $3+ billion market, giving investors reason to be excited. The company just announced that it will be initiating an upcoming field trial of comparison for Onychomycosis. The stock has surged over 50% in trading today and the stock has tripled since the beginning of March. VDRM has seen a significant expansion in volume which is a bullish development.

    VDRM is attempting to break into the Onychomycosis market with its TetraStem liquid based antibiotic. The market size of Onychomycosis treatment is estimated to be at approximately $3.5 billion in the USA markets alone. Onychomycosis is a fungal infection of the toenails or fingernails that may involve any part of the nail itself. This infection can cause pain, distress, and deformity that could produce serious physical and occupational restrictions, as well as affect quality of life. Recently registered as a medication by the FDA, TetraStem, that is designed to treat cuts, scrapes, and burns.

    Viaderma Inc (OTCMKTS:VDRM) introduced an upcoming trial that is expected to take place in the Springtime. The study will feature their leading product, TetraStem. In the trials patients will receive both treatments at 90-day, six months, nine months, and one year lapses of time. Previously used as an off-label treatment for Onychomycosis with proven results, ViaDerma believes that TetraStem will serve as a possible more effective and more affordable option than other leading brands.

    The company’s flagship product TetraStem has been seen in private off-label practice to hold an 86% success rate after only 12 weeks of use. Current competition has only seen an 18% success rate, requiring 48 weeks of patient use. Not only are these differences staggering, but to add to that, a bottle of TetraStem retails for only $39.99, whereas the same size has been sold for more than $500 through other brands.

    VDRM was founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets.
  13. [verwijderd] 7 april 2016 07:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    mks schreef op 5 april 2016 23:16:

    Heb ze ook gekocht voor de gok.
    140K .

    Top! kijken of je vandaag al op winst kan komen, na een kleine consolidatie dag gister.

  14. mks 9 april 2016 12:53

    • mks

      Lid sinds: 18 jul 2009

      Laatste bezoek: 21 sep 2023

    • Aanbevelingen

      Ontvangen: 5

      Gegeven: 11

    •    Aantal posts: 127

    quote:

    warren buffetttt schreef op 7 april 2016 07:49:

    [...]

    Top! kijken of je vandaag al op winst kan komen, na een kleine consolidatie dag gister.

    Hoppa de helft eraf,niet zo'n goede gok dus.

    Er zit een zekere Dutchdaan op I-Hub die aangeeft de CEO aan de telefoon te hebben gehad waarna hij zijn aandelen heeft verkocht ivm niet vertrouwenswekkend
    Dit ben jij toch niet ?
  15. Eekhoorn50 22 januari 2017 01:56

    • Eekhoorn50

      Lid sinds: 17 jun 2003

      Laatste bezoek: 05 apr 2024

    • Aanbevelingen

      Ontvangen: 57

      Gegeven: 18

    •    Aantal posts: 266

    Het is echt geen gok. Zeer gezond bedrijf. Een voorgangerbedrijf van dezelfde branche (Owcp) ging van september'16 tot nu van 0,003 naar
    0,95$.Stijgingen van 0,35$ per dag en meer waren er bij. Een verdere voorganger (Axim)heeft al de 19$ aangeraakt nu even teruggevallen naar 13$. Dan te bedenken dat deze bedrijven nog geen winst maken. Owcp vorig jaar een verlies van 1,7 miljoen. Viaderma al in de winst zoals hiervoor al aangegeven. Potentie is echt enorm. Reden waarom deze bedrijven zo gewild zijn is dat ze op het juiste moment de markt bedienen bij een terugtrekkend
    verbod op marijuana. Viaderma geeft ook een indicatie per ziektebestrijding van de marktpotentie met een te verwachten omzet in de miljarden. Dan blijkt de potentie!!!! Viaderma is de markt aan het veroveren in Amerika maar is nu al reeds bezig hun produkten te gaan verkopen in alle werelddelen. Nog meer potentie dus die gestadig zal groeien jaarlijks. Mooi vasthouden u gaat heel rijk worden.
  19. WEBJE 25 maart 2017 22:35

    • WEBJE

      Lid sinds: 05 okt 2011

      Laatste bezoek: 07 feb 2023

    • Aanbevelingen

      Ontvangen: 63

      Gegeven: 18

    •    Aantal posts: 2.038

    Nog iemand die dit aandeel volgt ,Heb mijn twijfels omtrent hun patenten ???
19 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.282
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.082
ABO-Group 1 18
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.867
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.146
Aedifica 2 828
Aegon 3.257 320.010
AFC Ajax 537 7.010
Affimed NV 2 5.734
ageas 5.843 109.775
Agfa-Gevaert 13 1.854
Ahold 3.536 73.977
Air France - KLM 1.024 34.302
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.682
Alfen 12 16.000
Allfunds Group 3 1.122
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 324
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.756
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.153
AMG 965 125.587
AMS 3 73
Amsterdam Commodities 303 6.512
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 381
Antonov 22.632 153.605
Aperam 91 14.103
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.575
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.092
Aroundtown SA 1 175
Arrowhead Research 5 9.248
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.529
ASML 1.762 76.466
ASR Nederland 18 4.117
ATAI Life Sciences 1 7
Atenor Group 1 322
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.622
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.657

Macro & Bedrijfsagenda

  1. 19 april

    1. Japan inflatie maart 2,7% YoY volitaliteit verwacht
    2. WDP Q1-cijfers
    3. EU producentenprijzen maart
    4. VK detailhandelsverkopen maart
    5. Fra ondernemersvertrouwen april
    6. KPN €0,098 ex-dividend
    7. CM.com jaarvergadering
    8. NSI jaarvergadering
    9. American Express Q1-cijfers

  2. 22 april

    1. NL investeringen februari
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda